Massive Bio and Mika Health have partnered to enhance patient access to psycho-oncology services, biomarker testing, and clinical trials.

The partnership expects to expand patients’ access to Mika’s Digital Therapeutic for treating oncology-related fatigue, anxiety, and depression. Subsequently, patients using Digital Therapeutic can opt into Massive Bio’s clinical trial matching and biomarker testing service, while Mika’s Digital Therapy will be available to Massive Bio's cancer patient registry. By leveraging AI-powered data-driven insights, the companies aim to provide personalized psychotherapy, symptom management, side-effect interception, and educational resources to their patients.

Mika Health, also known as Fosanis, is a digital health company headquartered in Germany that specializes in providing AI-powered precision medicine solutions designed to support cancer patients through the treatment process. The company’s proprietary "Mika" app offers a range of services, including symptom tracking, personalized guidance, and practical advice on managing cancer-related physical and emotional challenges.